Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01538719

IL1-TRAP, Rilonacept, in Systemic Sclerosis

Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial

Sponsor: Boston University

Conditions Diffuse Scleroderma Diffuse Systemic Sclerosis Scleroderma Systemic Sclerosis

Interventions Placebo Rilonacept

Updated 8 times since 2017 Last updated: Apr 2, 2018 Started: Dec 31, 2011 Primary completion: Jan 31, 2017 Completion: Aug 11, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Diffuse Scleroderma and Diffuse Systemic Sclerosis, this trial is completed. The trial is conducted by Boston University and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Apr 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Unknown Status → Active Not Recruiting
Feb 2017 — Apr 2017 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston University
Regeneron Pharmaceuticals

Data source: Boston University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States